BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

At least 14 therapies are in the clinic to treat cutaneous T cell lymphoma, a rare cancer of T lymphocytes that primarily affects the skin. The most common subtypes of CTCL are mycosis fungoides and...
BioCentury | Nov 13, 2020
Translation in Brief

Roche and Immune-Onc mAb data; plus Capricor’s exosome-based COVID-19 vaccine induces cellular immunity, and more

Roche’s mAb depletes regulatory T cellsRoche (SIX:ROG; OTCQX:RHHBY) and University College London scientists reported in Nature Cancer that the anti-CD25 mAb RG6292, which is in a Phase I trial in advanced...
BioCentury | Nov 11, 2020
Product Development

Arena sees clear path to atopic dermatitis Phase III for etrasimod despite data that shed $1B in value

...NYSE:ABBV) have demonstrated up to a 62% IGA...
BioCentury | Nov 10, 2020
Product Development

Reata, Calliditas make good on renewed interest in kidney disease with Phase III successes

...accelerated approval.Kidney diseases including Alport syndrome and IgA...
...for the indication.Calliditas has more competition in IgA...
BioCentury | Nov 7, 2020
Emerging Company Profile

IgGenix: antibody engineering for food allergies

IgGenix is pairing single-cell sequencing with antibody engineering to create a new class of food allergy therapies that selectively suppresses allergen-triggered immunity while sidestepping the risky steps of desensitizing immunotherapy.  The company launched in August with...
BioCentury | Oct 27, 2020
Distillery Therapeutics

UCSF team develops trivalent binder of SARS-CoV-2 spike for COVID-19

DISEASE CATEGORY: Infectious disease INDICATION: Coronavirus A UCSF team led by Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) founder Jim Wells has developed a trivalent immunoglobulin variable heavy domain-based inhibitor of the ACE2-SARS-CoV-2 S interaction that could treat COVID-19 infection....
BioCentury | Oct 22, 2020
Product Development

Data Byte: AbbVie’s oral JAK takes the lead in coming competition for Dupixent in atopic dermatitis

...Severity Index (EASI 75) and up to a 62% response rate for Investigator’s Global Assessment (IGA...
BioCentury | Oct 14, 2020
Management Tracks

Anderson joining Sofinnova Partners to bridge European biotechs to public markets

...to report this quarter data from the Phase III NefIgArd trial of Nefecon to treat IgA...
BioCentury | Oct 9, 2020
Product Development

COVID-19 Quick Takes: Moderna won’t challenge vaccine IP, wins contract for mobile GMP manufacturing

Moderna won’t enforce COVID-19 IP during pandemicModerna Inc. (NASDAQ:MRNA) said on Thursday it will not enforce its COVID-19 related patents against vaccine developers addressing SARS-CoV2 while the pandemic continues. It added that it is willing...
BioCentury | Oct 6, 2020
Deals

Oct. 5 Quick Takes: BridgeBio reacquiring Eidos, Amgen KRAS data, after-hours tumbles for Iovance, Y-mAbs and more

...to advance its kidney disease programs, including through planned Phase II and III trials of atrasentan for IgA...
Items per page:
1 - 10 of 1144